Login
$STAA
$24.16 +$0.93 (4.0%) Close

Company Executives

$STAA Management Team

Mr. Brian Moore

Vice President - Investor Relations and Corporate Development

Age -
Compensation -
Sex Male

Mr. Warren Foust

President

Interim Co-Chief Executive Officer

Chief Operating Officer

Age 50
Compensation $2.904M USD
Sex Male

Dr. Magda Michna

Chief Development Officer

Age 49
Compensation $2.314M USD
Sex Female

Ms. Deborah Andrews

Interim Co-Chief Executive Officer

Chief Financial Officer

Age 68
Compensation $389.4K USD
Sex Female

Mr. Neal Bradsher

Independent Chairman of the Board

Age 60
Compensation -
Sex Male
Directors
7
serving now
Independent
6 of 7
stated in the proxy
Average tenure
1.1 years
from year joined
CEO also chairs the board
No
Neal C. Bradsher
Director Age On board Independent Committees Other public boards 2025 pay Source
Neal C. Bradsher
60 2026
0 years
Independent None stated Lineage Cell Therapeutics, Inc. Not stated
Arthur C. Butcher
55 2024
2 years
Independent None stated Acotec Scientific Holdings Ltd. $243,394
Wei Jiang
62 2024
2 years
Not independent None stated Waters Corporation $1,536,047
Richard T. LeBuhn
61 2026
0 years
Independent None stated None stated Not stated
Louis E. Silverman
67 2025
1 year
Independent None stated Insight Molecular Diagnostics Inc. $254,787
Christopher M. Wang
55 2026
0 years
Independent None stated None stated Not stated
Lilian Y. Zhou
43 2023
3 years
Independent None stated None stated $448,571

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

5 disclosed in the proxy filed May 4, 2026
Wei Jiang
one of our directors
$1,275,000
fiscal 2025

Consulting agreement under which Mr. Jiang serves as special strategic advisor to the Asia Pacific business, compensated with RSUs

Wei Jiang
one of our directors
Amount not stated

Continued provision of standard non-employee director compensation to Mr. Jiang while serving as advisor

Broadwood
holder of more than 5% of the Company's outstanding stock
Amount not stated
January 14, 2026

Cooperation Agreement with Broadwood, including board size increase, director resignations and appointments, and nomination of New Directors

With the Company Open in proxy
Broadwood
holder of more than 5% of the Company's outstanding stock
$5,036,000

Reimbursement of fees and expenses paid to Broadwood under the Cooperation Agreement

With the Company Open in proxy
Yunqi Capital
holder of more than 5% of the Company's outstanding stock
$962,000

Reimbursement of fees and expenses paid to Yunqi Capital under the Cooperation Agreement

With the Company Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support